Anthem Biosciences Limited is a contract research, development, and manufacturing organization serving pharmaceutical and biotechnology companies. Its capabilities span drug discovery, development, biologics, formulation development, and manufacturing services across different stages of the pharmaceutical value chain. The company benefits from increasing outsourcing by global pharmaceutical and biotechnology companies. Growth in complex drug development and demand for outsourced research and manufacturing can expand its addressable market. Research pipelines, customer concentration, regulatory requirements, capacity expansion, and execution remain important considerations.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|
| ₹45,550 cr | — | — | 81.0 | 10.18 | 14.97 | 18.8% | 0.02 | ₹637 cr | 47.8 | 0.50 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Jun 2026 | 418 | 120 | 2.13 | -12.3% | -22.6% | 28.7% |
| Mar 2026 | 611 | — | — | — | — | — |
| Dec 2025 | 423 | 93 | 1.65 | — | — | 21.9% |
| Sep 2025 | 550 | 173 | 3.09 | — | — | 31.5% |
| Jun 2025 | 540 | 136 | 2.43 | — | — | 25.1% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | ✗ Fail |
| EPS growth accelerating over 3 quarters | — Not assessable |
| Sales up 25%+, or sales growth accelerating | ✗ Fail |
| Annual EPS up 25%+ in each of the last 2 years | — Not assessable |
| Net margin above the same quarter last year | ✓ Pass |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✓ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✓ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✗ Close above the 50-day ✓ At least 25% above the 52-week low · low 592.40 ✓ Within 25% of the 52-week high · high 957.80 ✗ RS percentile 70 or more · RS 66 Trend template - the gate, measured: a modest 21-day edge. | 6/8 | 6 of 8 |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 2 - advancing | |
| CAN SLIM | ✗ C latest quarter EPS up 25%+ — A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✗ N within 15% of the 52-week high · high 957.80 ✓ S more volume on up days than down days (50 sessions) · 1.29x ✗ L RS percentile 80 or more · RS 66 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist. | 2/5 | Weak |
| Darvas | ✓ Box top confirmed (3 sessions below the new high) · top 977.55 ✗ Box bottom confirmed (3 sessions holding) · bottom 816.60 ✗ Close above the box top · close 808.50 ✗ Volume at least 1.5x its 50-day average · 0.5x Nicolas Darvas's box: buy the breakout above a confirmed box after a new high. | 45/100 | In box |
| Turtle | ✗ Close above the prior 55-session high · 977.55 ✗ Close above the prior 20-session high · 952.90 ✓ Close below the prior 20-session low · 816.60 Donchian channel breakout - the Turtle traders' entry. | Breakdown | |
| Graham | ✗ Price at or below the Graham number · Graham number 111.22 ✗ P/E 15 or less · P/E 79.4 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 14.97 ✓ Current ratio 2 or more · 5.54 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 14/100 | Expensive |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANTHEM this stock | -12.9 | +2.1 | +11.6 | +6.7 | — | — | 81.0 | 14.97 | 18.8 | — | — | 0.02 | 47.8 | 45,550 | — | — | 10.2 | 0.50 |
| BLISSGVS | -8.0 | +29.9 | +147.2 | +312.3 | +606.5 | +476.9 | 48.7 | 5.57 | 11.5 | 16.8 | — | 0.00 | 29.3 | 6,650 | 1,005 | 142 | 12.9 | 1.10 |
| VENUSREM | +0.7 | -5.9 | +55.8 | +252.6 | +518.8 | +242.4 | 18.3 | 3.21 | 16.8 | 21.9 | — | 0.00 | 13.7 | 2,130 | 811 | 116 | 86.9 | 0.88 |
| INDSWFTLAB | -5.7 | +50.4 | +153.3 | +247.2 | +287.1 | +472.2 | 51.6 | 2.21 | 3.2 | 3.9 | — | 0.01 | 33.4 | 3,056 | 665 | 57 | 6.8 | 0.78 |
| MOREPENLAB | +0.5 | +108.6 | +194.2 | +152.6 | +242.7 | +132.7 | 47.5 | 5.34 | 7.9 | 10.1 | — | 0.16 | 40.2 | 6,657 | 1,951 | 140 | 2.6 | 1.46 |
| SHILPAMED | -14.2 | +40.1 | +113.1 | +146.1 | +421.3 | +189.7 | 57.3 | 6.61 | 9.8 | 11.4 | — | 0.25 | — | 17,130 | 1,682 | 297 | 15.3 | 0.87 |
| RUBICON | -15.1 | -1.7 | +60.3 | +140.3 | — | — | 83.8 | 19.08 | 22.4 | — | — | 0.20 | 61.3 | 24,587 | 1,936 | 288 | 17.7 | 0.34 |
| LAURUSLABS | +5.9 | +32.7 | +83.2 | +129.9 | +421.9 | +235.3 | 88.9 | 21.09 | 18.2 | 17.9 | — | 0.45 | 62.0 | 1.12L | 8,839 | 1,252 | 23.3 | 0.74 |
| ZIMLAB | +2.0 | +14.2 | +73.3 | +101.9 | +17.5 | — | 168.5 | 2.50 | 2.1 | 5.5 | — | 0.42 | 21.1 | 740 | 397 | 4 | 0.8 | 0.75 |
| ACUTAAS | -5.4 | -11.0 | +35.0 | +97.5 | — | — | 69.0 | 16.11 | 24.0 | 31.7 | — | 0.02 | 49.9 | 26,636 | 1,462 | 387 | 47.2 | 0.77 |
| IOLCP | -9.8 | +17.8 | +108.9 | +87.8 | +99.0 | +56.2 | 32.0 | 2.99 | 7.9 | 10.7 | — | 0.07 | 20.7 | 5,376 | 2,524 | 168 | 5.7 | 1.13 |